An unanimous verdict has been reached in favor of Natera in its patent infringement case against CareDx. The jury in the U.S. District Court for the District of Delaware awarded Natera a total of $96.3 million in damages. This includes $83.7 million in lost profits and $12.6 million in past royalties.
The jury found that CareDx's products, AlloSure and AlloSeq, infringe one of the two Natera patents asserted against CareDx. Furthermore, the jury determined that all asserted claims of both patents are valid on various grounds. In fact, the jury provided an advisory verdict to the judge, stating that all asserted claims of both patents are valid under 35 U.S.C. Sec. 101.
Moving forward, a schedule will be set for further proceedings to determine whether CareDx's future sales of new versions of AlloSeq and AlloSure also infringe the asserted Natera patents.
It is important to note that in a separate lawsuit, Natera successfully invalidated all three of CareDx's patents that were asserted against them. This decision was upheld on appeal.
This landmark verdict reaffirms the strength of Natera's intellectual property and recognizes the company's contributions to the field. Natera remains committed to protecting its innovations and ensuring fair competition in the market.
